A serum assay system for diagnosis of myasthenia gravis. The assay system includes a complex of acetylcholine receptor protein and a toxin labeled with a radioactive isotope. The complex is incubated with a serum sample from a patient. During incubation, antibodies engendered by myasthenia gravis bind to receptor sites in the complex. The resulting complex containing the antibodies is precipitated by addition of anti-immunoglobulin. Radioactivity in the resulting precipitate is measured and compared with a control.
|
1. A biochemical assay system comprising a complex of acetylcholine receptor protein derived from human mammalian muscle with toxin labeled with a radioactive isotope.
5. A diagnostic test for determination of myasthenia gravis comprising the steps of preparing a complex of acetylcholine receptor protein derived from human mammalian muscle, toxin and a radioactive isotope, incubating said complex with a serum sample from a patient so as to join antibodies engendered by myasthenia gravis to receptor in said complex, precipitating said antibody-complex with anti-immunoglobulin and measuring the radioactivity of said precipitate.
2. A biochemical assay system in accordance with
3. A biochemical assay system in accordance with
6. A diagnostic test in accordance with
7. A diagnostic test in accordance with
|
|||||||||||||||||
The present invention relates generally to a biochemical assay system for use in medical diagnosis. More particularly, the present invention relates to a bio-assay for myasthenia gravis and to the diagnosis of myasthenia gravis in humans.
Myasthenia gravis is a disease characterized by muscular weakness which particularly affects the muscles of the face, tongue and neck. Myasthenia gravis is commonly mistaken for other pathological and neurological disorders. Electromyogram response to repeated electrical nerve stimulation has been the best available diagnostic test for myasthenia gravis. However, electromyogram testing is not wholly satisfactory since this technique must be performed and evaluated by a specialized neurologist, and the effects observed are small. It would be desirable to provide a more reliable diagnostic test for determination of myasthenia gravis and one that would be accessible to any physician simply by assay of a sample of the patients serum in a clinical laboratory. Also, it would be especially desirable to have an easy method to assay patients response to immunosuppressive therapy.
Accordingly, it is a principal object of the present invention to provide a serum-assay system for diagnosis of myasthenia gravis. It is another object of the invention to provide a diagnostic method for determination of myasthenia gravis which is highly selective and which can distinguish myasthenia gravis from other diseases.
Generally, in accordance with various features of the present invention a complex of acetylcholine receptor protein (AChR) and a toxin labeled with a radioactive isotope is prepared. The complex is incubated with a serum sample from a patient. During incubation, anitbodies engendered by myasthenia gravis bind to AChR in the complex. The resulting complexes of anti-body-AChR-I125 -toxin are precipitated along with carrier immunoglobulin by addition of anti-immunoglobulin. Radioactivity in the resulting precipitate is measured and is compared with a control. The radioactivity measurement can be converted to a titer expressed as moles of the AChR binding sites for toxin which are bound by the antibody per liter.
Acetylcholine receptor protein (AChR) is extracted from mammalian muscle tissue. Preferably, the AChR is extracted from human muscle tissue, since non-human muscle tissue AChR provides a less effective antigen for human antibody. One volume of minced muscle tissue is homogenized in a high shear blendor at 4°C in 4 volumes of an aqueous salt solution. The aqueous salt solution is 0.1 M NaCl, 0.01 M NaPO4 (pH 7.0), and 0.01 M NaN3. The homogenized muscle tissue is then centrifuged for 30 minutes at 105 × g. The pellet resulting from the centrifugal separation is extracted with 2 volumes of the above described salt solution containing 2 percent by weight of a surfactant. A surfactant available under the tradename Triton X-100 from the Sigma Company is preferred. The extraction is effected by shaking the residue for 1 hour in the solution. After extraction, the mixture is centrifuged for 1 hour at 105 × g. The supernate from the centrifugation contains AChR at a level of 2 to 8× 10-10 M.
The toxin used in the complex may be any of the known toxins which bind to AChR. Such toxins are derived from cobras or sea snakes. Naja naja siamensis toxin and α bungarotoxin from Bungarus multicinctus have been found to be particularly effective and are preferred.
Purified toxin is labeled with any suitable radioactive isotope in accordance with standard procedures. I125 is preferred for reasons of cost and availability. The toxin is labeled with I125 according to standard techniques using chloramine T as follows: To 5 mci of carrier-free I125 (2.4× 10-9 moles) is added 10 microliters of 0.1 M NaPO4 buffer (pH 7.0) followed by sufficient 0.1 M HCl to neutralize the NaOH in which the I125 is shipped. Toxin (2.4× 10-8 moles) and NaI (2.4× 10-8 moles) are added in 40-50 microliters of 0.1 M NaPO4 (pH 7.0) to the neutralized I125. Chloramine T is added (10 microliters containing 2.8× 10-8 moles) and the solution is agitated for 10 minutes. The solution along with 100 microliters of buffer is applied to a Sephadex G 25 column (1× 10 cm). A complex of I125 -toxin elutes in the void volume along with 86 percent of the radioactivity. When the above procedure is repeated but NaI is omitted and the chloramine T is reduced to 0.93× 10-8 moles, the incorporation of I125 is 100 percent. Both methods produce a complex of I125 -toxin effective to label AChR.
AChR is complexed with the I125 -toxin by incubation with excess I125 -toxin for several hours. The I125 -toxin bound to AChR is measured by using a Sephadex G-200 column (10 cm× 1 cm) which separates I125 -toxin-AChR complexes from free I125 -toxin. Since AChR is present as a minor component of the muscle extract, it is highly specific labeling of AChR by I125 -toxin that gives the specific antigen used in this assay.
The concentration of serum antibodies from a blood sample of a patient which couple to the AChR complex is measured by a double precipitin assay. AChR complexed with I125 -toxin from either Naja naja siamensis or Bungarus multicinctus is incubated with diluted serum. Antibodies found in sera of patients with myasthenia gravis are attached to AChR during the incubation. The resulting complex of antibody-AChR-I125 -toxin is precipitated along with other immunoglobulin in the serum by addition of anti-immunoglobulin. Radioactivity in the resulting precipitate is then measured. Radioactivity in a precipitate obtained by omitting AChR from the reaction mixture is subtracted from this value to correct for radioactivity nonspecifically trapped in the pellet. Using the known specific radioactivity of I125 -toxin the corrected value for radioactivity in the pellet is converted to a titer expressed in moles of toxin binding sites bound per liter of serum. Virtually all patients having myasthenia gravis which were tested had high titers, whereas patients which did not have myasthenia gravis had low or no titers.
In a specific example of the present invention, the antibody-AChR titer of various human subjects known to be suffering from several neurological diseases was determined. Human AChR was extracted from human muscle tissue in accordance with the method described hereinabove. I125 -toxin was prepared in accordance with the method described above. Triplicate 1 ml aliquots of human AChR (5× 10-10 M) were labeled in the presence of I125 -toxin (1× 10-9 M) by incubation at 4°C for 4 hours. Triplicate 1 ml aliquots of I125 -toxin (1× 10-9 M, Naja naja siamensis) were also prepared to serve as a control. 5 microliters of serum obtained from the blood of the patient were added to each tube. After overnight incubation at 4°C, goat anti-human gammaglobulin (15 percent Na2 SO4 cut) was added. The amount of goat serum used was that which gave a maximum precipitate when tested with 5 microliters of normal human serum (usually about 15 microliters). After 4 hours incubation at 4°C the tubes were centrifuged, the pellet was washed once and the radioactivity of the pellet determined. The radioactivity of the I125 -toxin blanks was subtracted from the average value for the tubes containing AChR. The titer in terms of the average moles of the toxin binding sites which were bound by antibodies per liter was determined in accordance with the following formula: ##EQU1## where: Cpm=counts of radioactivity per minute. The results for the several nuerologic diseases investigated are set forth below in Table I.
| TABLE I |
| ______________________________________ |
| Anti-Human Muscle AChR Antibody Titer in Several Neurologic |
| Diseases |
| ______________________________________ |
| Num- Anti-AChR Titer |
| ber of (Average moles toxin |
| Sub- binding sites bound/ |
| Diagnosis jects liter × 10--10) |
| ______________________________________ |
| Myasthenia Gravis 50 85.0 |
| Control (no neurologic |
| disease) 35 0.26 |
| Myasthenia Syndrome |
| (Eaton-Lambert Syndrome) |
| 4 0.36 |
| Polymyositis 6 0.32 |
| Duchenne Muscular Dystrophy |
| 6 0.29 |
| Myotonic Dystrophy |
| 5 0 |
| Becker Dystrophy 4 0.39 |
| Fascioscapulohumeral Dystrophy |
| 2 0.90 |
| Limb-Girdle Syndrome |
| 6 0.27 |
| Charcot-Marie-Tooth Syndrome |
| 1 0.09 |
| Anterior Horn Cell Disease |
| 1 0.50 |
| Werdnig Hoffmann 1 0.70 |
| McArdle's Syndrome |
| 1 0 |
| Kugelberg-Welander Syndrome |
| 1 0.37 |
| Multiple Sclerosis |
| 6 0 |
| ______________________________________ |
It has been determined that the severity of myasthenia gravis in the subject is not always directly related to the titer as determined by the method of the invention. However, the titer is higher, on the average, for those patients which are more severely afflicted with myasthenia gravis. Fifty-three patients suffering from myasthenia gravis at various levels of severity were assayed in accordance with the bio-assay system of the invention. The results are set forth in Table II.
| TABLE II |
| ______________________________________ |
| Severity of Myasthenia Gravis and Anti-AChR Antibody Titer of |
| Serum |
| ______________________________________ |
| Intensity of M.G. |
| (by Modified Osserman |
| Number of Titer × 10-10 |
| criteria) Patients Range Average |
| ______________________________________ |
| Remission 4 .03-.75 .39 |
| Ocular 5 2.0-50.0 14.1 |
| Mild generalized |
| 21 0-300.0 77.3 |
| Moderately severe |
| 21 .88- 81.1 |
| 297.0 |
| Acute severe 1 250.0 |
| Late severe 1 16.0 |
| ______________________________________ |
It can be seen that the bio-assay system of the invention provides a positive diagnostic test for the determination of myasthenia gravis in humans. If the titer of a serum sample from the patient is above 2.0× 10-10 moles of toxin binding cites bound per liter, the patient can be positively identified as having myasthenia gravis and can be treated in accordance with known methods. If a serum sample from the patient has a titer in the range of 1.0 to 2.0× 10-10, myasthenia gravis can be suspected. If the titer falls below 1.0× 10-10, tests for other neurological diseases are then made on the patient.
| Patent | Priority | Assignee | Title |
| 4789640, | Jan 06 1986 | The Salk Institute for Biological Studies | Assays for myasthenia gravis |
| 5041389, | Jan 06 1986 | The Salk Institute for Biological Studies | Assays for myasthenia gravis |
| 7094400, | May 01 1987 | Takeda Pharmaceutical Company Limited | Transkaryotic implantation |
| Patent | Priority | Assignee | Title |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Mar 20 1978 | The Salk Institute for Biological Studies | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Date | Maintenance Schedule |
| Jul 31 1982 | 4 years fee payment window open |
| Jan 31 1983 | 6 months grace period start (w surcharge) |
| Jul 31 1983 | patent expiry (for year 4) |
| Jul 31 1985 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jul 31 1986 | 8 years fee payment window open |
| Jan 31 1987 | 6 months grace period start (w surcharge) |
| Jul 31 1987 | patent expiry (for year 8) |
| Jul 31 1989 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jul 31 1990 | 12 years fee payment window open |
| Jan 31 1991 | 6 months grace period start (w surcharge) |
| Jul 31 1991 | patent expiry (for year 12) |
| Jul 31 1993 | 2 years to revive unintentionally abandoned end. (for year 12) |